The official Drugs@FDA dataset lists original submission 1 for ANDA 078271 with status AP dated 2013-12-23, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090834 with status AP dated 2013-11-12, and names octreotide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091041 with status AP dated 2013-11-12, and names octreotide acetate among the application record's active ingredients.
The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.
DailyMed lists Structured Product Labeling version 5 for the reviewed Linaclotide label family with a published date of 2013-08-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 4 for the reviewed Linaclotide label family with a published date of 2013-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published rule 2013-07542, attributed to FDA and its parent HHS department, on 2013-04-09. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
The Federal Register published rule 2013-06126, attributed to FDA and its parent HHS department, on 2013-03-22. Its official title is “New Animal Drugs; Changes of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 200219 with status AP dated 2013-02-13, and names oxytocin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091280 with status AP dated 2013-01-25, and names desmopressin acetate among the application record's active ingredients.
The Federal Register published notice 2013-00507, attributed to FDA and its parent HHS department, on 2013-01-14. Its official title is “Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.